PDF herunterladen
CC BY-NC-ND 4.0 · Am J Perinatol 2020; 37(04): 421-429
DOI: 10.1055/s-0039-1681014
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis

Evan J. Anderson
1   Departments of Pediatrics and Medicine, Emory University School of Medicine, Atlanta, Georgia
,
John P. DeVincenzo
2   Departments of Pediatrics and Microbiology, Immunology, and Biochemistry, University of Tennessee School of Medicine, Memphis, Tennessee
,
Eric A. F. Simões
3   Section of Pediatric Infectious Disease, University of Colorado School of Medicine, Colorado School of Public Health, Children’s Hospital Colorado, Aurora, Colorado
,
Leonard R. Krilov
4   Division of Pediatric Infectious Disease, Children's Medical Center, NYU-Winthrop Hospital, Mineola, New York
,
Michael L. Forbes
5   Pediatric Critical Care Medicine, Akron Children's Hospital, Akron, Ohio
,
Pia S. Pannaraj
6   Division of Infectious Diseases, Children's Hospital Los Angeles, Los Angeles, California, Keck School of Medicine, University of Southern California, Los Angeles, California
,
Claudia M. Espinosa
7   Pediatric Infectious Diseases, University of Louisville, Louisville, Kentucky
,
Robert C. Welliver
8   Pediatric Infectious Diseases, Children’s Hospital at OU Medical Center, Oklahoma City, Oklahoma
,
Leslie I. Wolkoff
9   Division of Neonatology, Connecticut Children's Medical Center, Hartford, Connecticut
,
Ram Yogev
10   Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
,
Paul A. Checchia
11   Cardiac Intensive Care, Texas Children's Hospital, Houston, Texas
,
Joseph B. Domachowske
12   Pediatrics: Infectious Disease, SUNY Upstate Medical University, Syracuse, New York
,
Natasha Halasa
13   Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee
,
Scott J. McBride
14   United BioSource Corporation, Ann Arbor, Michigan
,
Veena R. Kumar
15   AstraZeneca, Gaithersburg, Maryland
,
Kimmie K. McLaurin
15   AstraZeneca, Gaithersburg, Maryland
,
Christopher P. Rizzo
15   AstraZeneca, Gaithersburg, Maryland
,
Christopher S. Ambrose
15   AstraZeneca, Gaithersburg, Maryland
› Institutsangaben Funding This study was sponsored by AstraZeneca. Editorial support was provided by The Lockwood Group, which was in accordance with Good Publication Practice (GPP3) guidelines and funded by AstraZeneca.
Weitere Informationen

Publikationsverlauf

27. Dezember 2018

22. Januar 2019

Publikationsdatum:
16. April 2019 (online)

   Lizenzen und Reprints

Abstract

Objective The SENTINEL1 observational study characterized confirmed respiratory syncytial virus hospitalizations (RSVH) among U.S. preterm infants born at 29 to 35 weeks' gestational age (wGA) not receiving respiratory syncytial virus (RSV) immunoprophylaxis (IP) during the 2014 to 2015 and 2015 to 2016 RSV seasons.

Study Design All laboratory-confirmed RSVH at participating sites during the 2014 to 2015 and 2015 to 2016 RSV seasons (October 1–April 30) lasting ≥24 hours among preterm infants 29 to 35 wGA and aged <12 months who did not receive RSV IP within 35 days before onset of symptoms were identified and characterized.

Results Results were similar across the two seasons. Among infants with community-acquired RSVH (N = 1,378), 45% were admitted to the intensive care unit (ICU) and 19% required invasive mechanical ventilation (IMV). There were two deaths. Infants aged <6 months accounted for 78% of RSVH observed, 84% of ICU admissions, and 91% requiring IMV. Among infants who were discharged from their birth hospitalization during the RSV season, 82% of RSVH occurred within 60 days of birth hospitalization discharge.

Conclusion Among U.S. preterm infants 29 to 35 wGA not receiving RSV IP, RSVH are often severe with almost one-half requiring ICU admission and about one in five needing IMV.

Keywords

respiratory syncytial virus - infants - palivizumab - immunoprophylaxis - hospitalizations

Note

Portions of this work were presented at IDWeek 2016, New Orleans, LA, October 26–30, 2016; the Society of Critical Care Medicine's 46th Critical Care Congress, Honolulu, Hawaii, January 21–25, 2017; the Pediatric Academic Societies (PAS) 2017 Meeting, San Francisco, CA, May 6–9, 2017; IDWeek 2017, San Diego, CA, October 4–8, 2017; and the PAS 2018 Meeting, Toronto, ON, Canada, May 5–8, 2018.


Supplementary Material

 

  • References

  • 1 Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003; 143 (5, Suppl): S127-S132
    PubMedGoogle Scholar
  • 2 Mandell GL, Bennett JE, Dolin R. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 4th ed. New York: Churchill Livingstone; 1995
    Google Scholar
  • 3 Jain S, Williams DJ, Arnold SR. , et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372 (09) 835-845
    CrossrefPubMedGoogle Scholar
  • 4 Boyce TG, Mellen BG, Mitchel Jr EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137 (06) 865-870
    CrossrefPubMedGoogle Scholar
  • 5 Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J 2011; 30 (06) 510-517
    CrossrefPubMedGoogle Scholar
  • 6 Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000; 154 (01) 55-61
    PubMedGoogle Scholar
  • 7 Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003; 143 (5, Suppl): S133-S141
    PubMedGoogle Scholar
  • 8 Law BJ, Langley JM, Allen U. , et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004; 23 (09) 806-814
    CrossrefPubMedGoogle Scholar
  • 9 DeVincenzo JP, McClure MW, Symons JA. , et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 2015; 373 (21) 2048-2058
    CrossrefPubMedGoogle Scholar
  • 10 DeVincenzo JP, Whitley RJ, Mackman RL. , et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014; 371 (08) 711-722
    CrossrefPubMedGoogle Scholar
  • 11 Simões EA, DeVincenzo JP, Boeckh M. , et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis 2015; 211 (Suppl. 01) S1-S20
    CrossrefPubMedGoogle Scholar
  • 12 IMpact RSV-Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-537
    CrossrefPubMedGoogle Scholar
  • 13 Blanken MO, Rovers MM, Molenaar JM. , et al; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013; 368 (19) 1791-1799
    CrossrefPubMedGoogle Scholar
  • 14 Anderson EJ, Carosone-Link P, Yogev R, Yi J, Simões EAF. Effectiveness of palivizumab in high-risk Infants and children: a propensity score weighted regression analysis. Pediatr Infect Dis J 2017; 36 (08) 699-704
    CrossrefPubMedGoogle Scholar
  • 15 American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102 (05) 1211-1216
    CrossrefPubMedGoogle Scholar
  • 16 American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112 (6 Pt 1): 1442-1446
    CrossrefPubMedGoogle Scholar
  • 17 American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006; 118 (04) 1774-1793
    CrossrefPubMedGoogle Scholar
  • 18 Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements--modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124 (06) 1694-1701
    CrossrefPubMedGoogle Scholar
  • 19 American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS. , eds. Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012: 609-618
    Google Scholar
  • 20 American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134 (02) 415-420
    CrossrefPubMedGoogle Scholar
  • 21 Boyce TG. More on viral bronchiolitis in children. N Engl J Med 2016; 375 (12) 1199-1200
    CrossrefPubMedGoogle Scholar
  • 22 Goldstein M, Merritt TA, Phillips R. , et al. National Perinatal Association 2015 Respiratory Syncytial Virus (RSV) Prevention Guideline. Neonatology Today [serial online]. 2014;9:1–11. Available at: https://www.neonatologytoday.net/issues.php#2014issues . Accessed August 15, 2018
    PubMedGoogle Scholar
  • 23 Anderson EJ, Krilov LR, DeVincenzo JP. , et al. SENTINEL1: an observational study of respiratory syncytial virus hospitalizations among US infants born at 29 to 35 weeks' gestational age not receiving immunoprophylaxis. Am J Perinatol 2017; 34 (01) 51-61
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 24 Ambrose CS, Anderson EJ, Simões EA. , et al. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J 2014; 33 (06) 576-582
    CrossrefPubMedGoogle Scholar
  • 25 Helfrich AM, Nylund CM, Eberly MD, Eide MB, Stagliano DR. Healthy late-preterm infants born 33-36+6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization. Early Hum Dev 2015; 91 (09) 541-546
    CrossrefPubMedGoogle Scholar
  • 26 Winterstein AG, Knox CA, Kubilis P, Hampp C. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study. JAMA Pediatr 2013; 167 (12) 1118-1124
    CrossrefPubMedGoogle Scholar
  • 27 Rajah B, Sánchez PJ, Garcia-Maurino C, Leber A, Ramilo O, Mejias A. Impact of the updated guidance for palivizumab prophylaxis against respiratory syncytial virus infection: a single center experience. J Pediatr 2017; 181: 183-188
    CrossrefPubMedGoogle Scholar
  • 28 Blanken MO, Paes B, Anderson EJ. , et al. Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants. Pediatr Pulmonol 2018; 53 (05) 605-612
    CrossrefPubMedGoogle Scholar
  • 29 Kong AM, Krilov LR, Fergie J. , et al. The 2014–2015 national impact of the 2014 American Academy of Pediatrics guidance for respiratory syncytial virus immunoprophylaxis on preterm infants born in the United States. Am J Perinatol 2018; 35 (02) 192-200
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 30 Goldstein M, Krilov LR, Fergie J. , et al. Respiratory syncytial virus hospitalizations among US preterm infants compared with term infants before and after the 2014 American Academy of Pediatrics guidance on immunoprophylaxis: 2012–2016. Am J Perinatol 2018; 35 (14) 1433-1442
    Artikel in Thieme ConnectPubMedGoogle Scholar